Summary: Axsome Therapeutics In. is set to present multiple studies on AXS-12 and solriamfetol at Sleep Europe 2024, the 27th Congress of the European Sleep Research Society. These presentations include topline results from the phase 3 SYMPHONY trial of AXS-12 for narcolepsy, … [Read more...]
AXS-12 Reduces Narcolepsy Symptoms in Phase 3 Trial
Summary: In the SYMPHONY stage 3 trial, Axsome Therapeutics’ AXS-12 considerably lowered weekly cataplexy assaults and improved indications of narcolepsy, which include extreme daytime sleepiness, cognitive operate, and over-all ailment severity, when compared to placebo. The … [Read more...]